Post Title

The Direct‑to‑Consumer (D2C) pathway is quickly becoming one of the most exciting opportunities for health tech innovators — especially as XR technologies become more commonplace.

With a rapidly expanding market and growing consumer appetite for immersive, personalised health solutions, D2C offers founders a chance to move fast, build strong brand loyalty, and tap into significant revenue potential.

However, while the case for selling straight to the public is strong, the journey is rarely straightforward.

Below are 10 key insights from Dr Emilios Lemoniatis, Consultant Child and Adolescent Psychiatrist and CEO and CCIO of Medical Creatives Ltd, about how innovators can navigate the challenges of D2C to build commercially
viable products.

Building a product that people are willing to pay for is no small feat. Competition is intense, consumer expectations are high, plus you’ll need to price it so it supports sustainable growth without deterring potential customers.

Yet for health‑tech innovators seeking meaningful, scalable revenue, the consumer market remains one of the richest arenas for commercial opportunity.

When you get the value proposition and pricing right, it’s where transformative ideas have the potential to reach millions and make a measurable impact.

A product built for clinicians won’t automatically click with everyday consumers and that’s where many health tech teams hit a wall. Often, the most transformative move isn’t changing the product at all, but reframing it: sharpening the value proposition, focusing on a segment that truly cares, or highlighting benefits in a way that resonates with people who are willing to pay. If fast revenue is the goal, you may need to focus on a different audience.

Passion can spark great ideas, but it can also make it hard to see things objectively. What feels groundbreaking to you may not resonate the same way in the real world. That’s why real‑world testing, honest user feedback, and true market validation should guide your decisions. In a direct‑to‑consumer model, people vote with their wallets — and that’s ultimately the feedback that matters most. Use focus groups early to gather meaningful insights before you go too far down the wrong path.

Many early health tech products grow up inside grant cycles. This environment is supportive but often insulated from commercial pressure. Grants can unintentionally act like a greenhouse, nurturing ideas without exposing them to the realities of the market. When you leave that safe, protected environment, you have to be ready for the real world: customers who care about price, lots of competitors, higher expectations from users, and the need to show that people actually want what you’re offering.

When you rely on a single funding source, like grants, your business can become unexpectedly vulnerable. If that one stream dries up, your momentum goes with it. By blending income sources, including Direct-to-Consumer revenue, you give yourself greater resilience and stability, along with the strategic flexibility you need to grow with confidence rather than dependency.

The “Farmer’s Market” approach
Direct-to-Consumer demands a different kind of presence: direct, personal, and fuelled by real energy. It’s not enough to have a great product; you need compelling storytelling and the confidence to communicate its value in a way that resonates instantly. In this space, your ability to articulate the “why” is just as important as the “what.”

Market‑driven selling
Consumer-facing models are shaped by what people already want, how much they’re‑facing models are shaped by what people already want, how much they’re willing to pay, and what they expect in return including all the unspoken assumptions around support, service, and overall experience. Once you understand which model you’re actually operating in, everything else becomes clearer: how you build, how you sell, and how you grow.

Successful Direct-to-Consumer health tech isn’t driven by demographics, it’s driven by psychology. The real questions are: Who wants your product? Why do they want it? What emotions are shaping their decision? And crucially, how do they expect to feel after they’ve paid you? People don’t just like or dislike a brand. Their feelings are mixed, emotional, and shaped by every interaction they have with you from the very beginning.

NHS procurement pathways can be complex, slow, and fiercely competitive. For many innovators, that makes Direct-to-Consumer a far more straightforward way to prove value in the real world. When people willingly pay for your product, it shows strong proof that they value it. It also gives you a clear, fast way to show real impact.  This evidence can then be used to support NHS procurement later.

It is important that you check the regulatory requirements that fit your product’s intended purpose.

For B2C
Selling direct to consumers does not absolve the need to consider regulation – it’s all about the intended purpose. Products in this space typically sit in the wellness or self-help space, and may not need medical device classification.

For B2B
CE/UKCA marking and a full regulatory pathway may be required to meet procurement requirements.

Being open to framing your product differently for different audiences can unlock opportunities you didn’t even realise were available. A shift in perspective, including a shift in language, can reveal entirely new pathways for growth, relevance, and revenue.

The healthcare system is under pressure, and people increasingly trust recommendations from those they know. That means you can benefit massively from word‑of‑mouth as a driver of growth. When you create a product that helps people and feels meaningful, they naturally tell others about it.

• Marketplace analysis
  What analysis have I done? Who else is operating in my space, and what does my consumer landscape look like?
• Reframing
  Can my product be framed or used in different ways? Are there alternative audiences, use cases, or value propositions that make commercial sense?

• Government response to the Digital, Culture, Media & Sport Select Committee Report on Immersive and Addictive Technologies

• MHRA issues new guidance for people using mental health apps and technologies